JULIE CATLIN: Open Payments
NPI 1902907827 · ANNAPOLIS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,601 in 250 payments from 23 companies in 2025. Trend: 2023 $3,703 · 2024 $4,126 · 2025 $4,601
Food & beverage: $4,601
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 59 | $979 |
| ABBVIE INC. | 35 | $622 |
| UCB, Inc. | 27 | $521 |
| Regeneron Healthcare Solutions, Inc. | 20 | $346 |
| GENZYME CORPORATION | 11 | $324 |
| Novartis Pharmaceuticals Corporation | 19 | $311 |
| Lilly USA, LLC | 10 | $270 |
| Amgen Inc. | 14 | $230 |
| Arcutis Biotherapeutics, Inc. | 8 | $202 |
| Incyte Corporation | 9 | $158 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, Bimzelx, OTEZLA, Zoryve, COSENTYX, TALTZ.
Industry payments across MD — which companies pay providers there.
